急性髓系白血病的新型治疗药物
Emerging therapeutic drugs for AML.
作者信息
Stein Eytan M, Tallman Martin S
机构信息
Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
出版信息
Blood. 2016 Jan 7;127(1):71-8. doi: 10.1182/blood-2015-07-604538. Epub 2015 Dec 10.
Abstract
Multiple new drugs are being developed to treat acute myeloid leukemia (AML), including novel formulations of traditional chemotherapy-antibody drug conjugates and agents that target specific mutant enzymes. Next-generation sequencing has allowed us to discover the genetic mutations that lead to the development and clinical progression of AML. Studies of clonal hierarchy suggest which mutations occur early and dominate. This has led to targeted therapy against mutant driver proteins as well as the development of drugs such as CPX-351 and SGN-CD33A whose mechanisms of action and efficacy may not be dependent on mutational complexity. In this brief review, we discuss drugs that may emerge as important for the treatment of AML in the next 10 years.
摘要
多种新药正在研发用于治疗急性髓系白血病（AML），包括传统化疗 - 抗体药物偶联物的新型制剂以及靶向特定突变酶的药物。新一代测序技术使我们能够发现导致AML发生和临床进展的基因突变。对克隆层次结构的研究表明哪些突变发生较早并占主导地位。这导致了针对突变驱动蛋白的靶向治疗以及诸如CPX - 351和SGN - CD33A等药物的开发，其作用机制和疗效可能不依赖于突变复杂性。在这篇简短的综述中，我们讨论了未来10年可能对AML治疗具有重要意义的药物。
相似文献
1
Emerging therapeutic drugs for AML.急性髓系白血病的新型治疗药物
Blood. 2016 Jan 7;127(1):71-8. doi: 10.1182/blood-2015-07-604538. Epub 2015 Dec 10.
2
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.SGN-CD33A：一种新型的靶向 CD33 的抗体药物偶联物，使用吡咯苯并二氮杂䓬二聚体，在耐药 AML 模型中具有活性。
Blood. 2013 Aug 22;122(8):1455-63. doi: 10.1182/blood-2013-03-491506. Epub 2013 Jun 14.
3
Investigational CD33-targeted therapeutics for acute myeloid leukemia.针对急性髓细胞白血病的 CD33 靶向治疗药物的研究。
Expert Opin Investig Drugs. 2018 Apr;27(4):339-348. doi: 10.1080/13543784.2018.1452911. Epub 2018 Mar 15.
4
Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia.在急性髓系白血病复发患者中引入下一代测序的临床潜力。
Hematol Oncol. 2020 Oct;38(4):425-431. doi: 10.1002/hon.2739. Epub 2020 May 6.
5
How I treat acute myeloid leukemia in the era of new drugs.如何在新药时代治疗急性髓系白血病。
Blood. 2020 Jan 9;135(2):85-96. doi: 10.1182/blood.2019001239.
6
Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.精准医学和新型分子靶向治疗在急性髓系白血病中的应用：血液恶性肿瘤（HM）-SCREEN-Japan 01 的背景。
Int J Clin Oncol. 2019 Aug;24(8):893-898. doi: 10.1007/s10147-019-01467-1. Epub 2019 May 20.
7
Updates on DNA methylation modifiers in acute myeloid leukemia.急性髓系白血病中 DNA 甲基化修饰物的研究进展。
Ann Hematol. 2020 Apr;99(4):693-701. doi: 10.1007/s00277-020-03938-2. Epub 2020 Feb 6.
8
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.米哚妥林/PKC412用于治疗新诊断的FLT3突变阳性急性髓系白血病。
Expert Rev Hematol. 2017 Dec;10(12):1033-1045. doi: 10.1080/17474086.2017.1397510. Epub 2017 Oct 30.
9
Novel Treatment Paradigms in Acute Myeloid Leukemia.急性髓细胞白血病的新型治疗策略。
Clin Pharmacol Ther. 2020 Sep;108(3):506-514. doi: 10.1002/cpt.1962. Epub 2020 Aug 11.
10
New drug approvals in acute myeloid leukemia: an unprecedented paradigm shift.急性髓系白血病的新药批准：前所未有的范式转变。
Clin Adv Hematol Oncol. 2019 Oct;17(10):569-575.
引用本文的文献
1
The RNA-binding protein CELF1 targets ATG5 to regulate autophagy and promote drug resistance in acute myeloid leukemia.RNA结合蛋白CELF1靶向ATG5以调节自噬并促进急性髓系白血病的耐药性。
Cell Death Dis. 2025 Aug 8;16(1):599. doi: 10.1038/s41419-025-07926-0.
2
Identification of glucuronic acid as a biomarker of poor prognosis in acute myeloid leukemia based on plasma metabolomics.基于血浆代谢组学鉴定葡萄糖醛酸作为急性髓系白血病预后不良的生物标志物
Clin Exp Med. 2025 Apr 10;25(1):111. doi: 10.1007/s10238-025-01605-2.
3
TIFAB modulates metabolic pathways in KMT2A::MLLT3-induced AML through HNF4A.TIFAB通过HNF4A调节KMT2A::MLLT3诱导的急性髓系白血病中的代谢途径。
Blood Adv. 2025 Feb 25;9(4):844-855. doi: 10.1182/bloodadvances.2024013446.
4
Synergistic Effects of Glutamine Deprivation and Metformin in Acute Myeloid Leukemia.谷氨酰胺剥夺与二甲双胍在急性髓系白血病中的协同作用。
Curr Med Sci. 2024 Aug;44(4):799-808. doi: 10.1007/s11596-024-2913-z. Epub 2024 Aug 3.
5
Study of the intestinal microbiota composition and the effect of treatment with intensive chemotherapy in patients recovered from acute leukemia.研究急性白血病患者经强化化疗治疗后肠道微生物群落组成的变化及其影响。
Sci Rep. 2024 Mar 7;14(1):5585. doi: 10.1038/s41598-024-56054-w.
6
A Metabolome and Microbiome Analysis of Acute Myeloid Leukemia: Insights into the Carnosine-Histidine Metabolic Pathway.急性髓系白血病的代谢组和微生物组分析：对肌肽-组氨酸代谢途径的见解
Toxics. 2023 Dec 22;12(1):14. doi: 10.3390/toxics12010014.
7
Codelivery of BCL2 and MCL1 Inhibitors Enabled by Phenylboronic Acid-Functionalized Polypeptide Nanovehicles for Synergetic and Potent Therapy of Acute Myeloid Leukemia.基于苯硼酸功能化多肽纳米载体共递送 BCL2 和 MCL1 抑制剂用于协同强效急性髓系白血病治疗。
Adv Sci (Weinh). 2023 Mar;10(8):e2204866. doi: 10.1002/advs.202204866. Epub 2023 Jan 22.
8
Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model.抗体药物偶联物 ASP1235 靶向 Fms 样酪氨酸激酶 3 联合维奈克拉和阿扎胞苷在急性髓系白血病异种移植小鼠模型中的抗肿瘤作用。
Oncotarget. 2022 Dec 20;13:1359-1368. doi: 10.18632/oncotarget.28331.
9
HSF1 is a driver of leukemia stem cell self-renewal in acute myeloid leukemia.HSF1 是急性髓系白血病中白血病干细胞自我更新的驱动因子。
Nat Commun. 2022 Oct 16;13(1):6107. doi: 10.1038/s41467-022-33861-1.
10
The research progress of targeted therapy in acute myeloid leukemia based on bibliometric analysis.基于文献计量分析的急性髓系白血病靶向治疗研究进展
Front Oncol. 2022 Sep 2;12:957370. doi: 10.3389/fonc.2022.957370. eCollection 2022.
本文引用的文献
1
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.伏沙罗辛联合阿糖胞苷对比安慰剂联合阿糖胞苷治疗初治复发或难治性急性髓系白血病患者（VALOR）：一项随机、对照、双盲、多中心3期研究
Lancet Oncol. 2015 Sep;16(9):1025-1036. doi: 10.1016/S1470-2045(15)00201-6. Epub 2015 Jul 30.
2
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.阿扎胞苷对比传统治疗方案用于新诊断的原始细胞比例>30%的老年急性髓系白血病患者的国际3期研究。
Blood. 2015 Jul 16;126(3):291-9. doi: 10.1182/blood-2015-01-621664. Epub 2015 May 18.
3
DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.DOT1L抑制SIRT1介导的表观遗传沉默，以维持MLL重排白血病中的白血病基因表达。
Nat Med. 2015 Apr;21(4):335-43. doi: 10.1038/nm.3832. Epub 2015 Mar 30.
4
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.伏沙罗辛及伏沙罗辛联合小剂量阿糖胞苷（LDAC）与单纯小剂量阿糖胞苷治疗老年急性髓系白血病的疗效比较
Blood. 2015 May 7;125(19):2923-32. doi: 10.1182/blood-2014-10-608117. Epub 2015 Mar 24.
5
Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia.靶向治疗临床研发的当前挑战：以急性髓系白血病为例。
Blood. 2015 Apr 16;125(16):2461-6. doi: 10.1182/blood-2015-01-561373. Epub 2015 Mar 11.
6
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.异柠檬酸脱氢酶1和2突变在急性髓系白血病中诱导对BCL-2的依赖性。
Nat Med. 2015 Feb;21(2):178-84. doi: 10.1038/nm.3788. Epub 2015 Jan 19.
7
MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition.混合谱系白血病（MLL）部分串联重复白血病细胞对小分子DOT1L抑制敏感。
Haematologica. 2015 May;100(5):e190-3. doi: 10.3324/haematol.2014.115337. Epub 2015 Jan 16.
8
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.REVEAL-1研究，一项关于伏沙罗辛在既往未经治疗的急性髓系白血病老年高危患者中的2期剂量方案优化研究。
Br J Haematol. 2015 Mar;168(6):796-805. doi: 10.1111/bjh.13214. Epub 2014 Nov 17.
9
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.CPX-351（阿糖胞苷：柔红霉素）脂质体注射剂与强化挽救疗法治疗初治复发急性髓系白血病成人患者的多中心随机II期试验
Cancer. 2015 Jan 15;121(2):234-42. doi: 10.1002/cncr.28974. Epub 2014 Sep 15.
10
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.低剂量阿糖胞苷联合或不联合沃拉替尼用于不适合诱导治疗的急性髓系白血病患者的随机2期试验。
Blood. 2014 Aug 28;124(9):1426-33. doi: 10.1182/blood-2014-03-560557. Epub 2014 Jul 8.
Zotero 插件